Hayashi K, et al. - Researchers assessed the incidence of late relapse hepatitis C virus in patients who achieved sustained virological responses (SVR) with daclatasvir (DCV) and asunaprevir (ASV). Analysis of 413 patients infected with hepatitis C virus (HCV) genotype 1b who completed ASV and DCV treatment and achieved SVR revealed redevelopment of HCV RNA in the serum of 4 patients at 6, 12, 12, and 26 months, respectively, after achieving SVR24. Results of molecular analysis indicated that the same strain was present at pretreatment and late relapse. Despite the possibility of development of late relapse in few patients, SVR achieved with all oral DAA therapy is as durable as that with IFN therapy.